Polyglutamine toxicity is controlled by prion composition and gene dosage in yeast

PLoS Genetics

Volumn 8, Issue 4, 2012, Pages

  Gong, He ^a,d   Romanova, Nina V ^a,e   Allen, Kim D ^a,f   Chandramowlishwaran, Pavithra ^a   Gokhale, Kavita ^a   Newnam, Gary P ^a   Mieczkowski, Piotr ^b   Sherman, Michael Y ^c   Chernoff, Yury O ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE; PRION PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE; RNQ1 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN; SUP35 PROTEIN, S CEREVISIAE; SUP45 PROTEIN, S CEREVISIAE; TRANSLATION TERMINATION FACTOR;

AGGRESOME; ALLELE; ARTICLE; DISOMY; EPIGENETICS; EUKARYOTIC CELL; GENE; GENE DOSAGE; GENE LOCUS; GENETIC CROSS; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; SUP35 GENE; SUP45 GENE; YEAST; CHEMISTRY; GENE DELETION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PRION; PROTEIN BINDING; PROTEIN SYNTHESIS; SACCHAROMYCES CEREVISIAE;

EUKARYOTA; MAMMALIA;

EPIGENESIS, GENETIC; GENE DOSAGE; HUMANS; NERVE TISSUE PROTEINS; PEPTIDE TERMINATION FACTORS; PEPTIDES; PRIONS; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE DELETION;

EID: 84860594894     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002634     Document Type: Article

References (80)

1. Shao J, Diamond MI, (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16: R115-123.
2. La Spada AR, Taylor JP, (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11: 247-258.
3. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
4. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
5. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259-269.
6. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
7. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, et al. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 490: 354-370.
8. Zoghbi HY, Orr HT, (1999) Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol 9: 566-570.
9. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97: 6763-6768.
10. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13: 1389-1405.
11. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595.
12. Yamanaka T, Tosaki A, Miyazaki H, Kurosawa M, Furukawa Y, et al. (2010) Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction. Hum Mol Genet 19: 2099-2112.
13. Ross CA, Poirier MA, (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl): S10-17.
14. Hands SL, Wyttenbach A, (2010) Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathol 120: 419-437.
15. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
16. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549-558.
17. Ross CA, Wood JD, Schilling G, Peters MF, Nucifora FC Jr, et al. (1999) Polyglutamine pathogenesis. Philos Trans R Soc Lond B Biol Sci 354: 1005-1011.
18. Ross CA, Tabrizi SJ, (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83-98.
19. Johnston JA, Ward CL, Kopito RR, (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143: 1883-1898.
20. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, et al. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12: 1393-1407.
21. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, et al. (2003) Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 12: 749-757.
22. Olzmann JA, Li L, Chin LS, (2008) Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 15: 47-60.
23. Kopito RR, (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10: 524-530.
24. Garcia-Mata R, Gao YS, Sztul E, (2002) Hassles with taking out the garbage: aggravating aggresomes. Traffic 3: 388-396.
25. Olzmann JA, Li L, Chudaev MV, Chen J, Perez FA, et al. (2007) Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 178: 1025-1038.
26. Chin LS, Olzmann JA, Li L, (2010) Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem Soc Trans 38: 144-149.
27. Bondzi C, Brunner AM, Munyikwa MR, Connor CD, Simmons AN, et al. (2011) Recruitment of the oncoprotein v-ErbA to aggresomes. Mol Cell Endocrinol 332: 196-212.
28. Krobitsch S, Lindquist S, (2000) Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA 97: 1589-1594.
29. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, et al. (2000) Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 97: 7841-7846.
30. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, et al. (2002) Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 157: 997-1004.
31. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S, (2006) A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci USA 103: 11051-11056.
32. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S, (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA 103: 11045-11050.
33. Duennwald ML, (2011) Polyglutamine misfolding in yeast: toxic and protective aggregation. Prion 5: 285-290.
34. Mason RP, Giorgini F, (2011) Modeling Huntington disease in yeast: perspectives and future directions. Prion 5: 269-276.
35. Gokhale KC, Newnam GP, Sherman MY, Chernoff YO, (2005) Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem 280: 22809-22818.
36. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T, Engel A, et al. (2007) Yeast prions: evolution of the prion concept. Prion 1: 94-100.
37. Tuite MF, Cox BS, (2003) Propagation of yeast prions. Nat Rev Mol Cell Biol 4: 878-890.
38. Inge-Vechtomov SG, Zhouravleva GA, Chernoff YO, (2007) Biological roles of prion domains. Prion 1: 228-235.
39. Meriin AB, Zhang X, Miliaras NB, Kazantsev A, Chernoff YO, et al. (2003) Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol 23: 7554-7565.
40. Meriin AB, Zhang X, Alexandrov IM, Salnikova AB, Ter-Avanesian MD, et al. (2007) Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J 21: 1915-1925.
41. Caviston JP, Holzbaur EL, (2009) Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19: 147-155.
42. Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, et al. (2009) Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J 23: 451-463.
43. Urakov VN, Vishnevskaya AB, Alexandrov IM, Kushnirov VV, Smirnov VN, et al. (2010) Interdependence of amyloid formation in yeast: implications for polyglutamine disorders and biological functions. Prion 4: 45-52.
44. Seufert W, Jentsch S, (1990) Ubiquitin-conjugating enzymes UBC4 and UBC5 mediate selective degradation of short-lived and abnormal proteins. EMBO J 9: 543-550.
45. Stansfield I, Jones KM, Kushnirov VV, Dagkesamanskaya AR, Poznyakovski AI, et al. (1995) The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae. EMBO J 14: 4365-4373.
46. Kallmeyer AK, Keeling KM, Bedwell DM, (2006) Eukaryotic release factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in Saccharomyces cerevisiae. Eukaryot Cell 5: 1378-1387.
47. Moskalenko SE, Zhuravleva GA, Soom M, Shabel'skaia SV, Volkov KV, et al. (2004) Characterization of missense mutations in the SUP45 gene of Saccharomyces cerevisiae encoding translation termination factor eRF1. Genetika 40: 599-606.
48. Kaganovich D, Kopito R, Frydman J, (2008) Misfolded proteins partition between two distinct quality control compartments. Nature 454: 1088-1095.
49. Vishveshwara N, Bradley ME, Liebman SW, (2009) Sequestration of essential proteins causes prion associated toxicity in yeast. Mol Microbiol 73: 1101-1114.
50. Valouev IA, Kushnirov VV, Ter-Avanesyan MD, (2002) Yeast polypeptide chain release factors eRF1 and eRF3 are involved in cytoskeleton organization and cell cycle regulation. Cell Motil Cytoskeleton 52: 161-173.
51. Dagkesamanskaya AR, Ter-Avanesyan MD, (1991) Interaction of the yeast omnipotent suppressors SUP1(SUP45) and SUP2(SUP35) with non-mendelian factors. Genetics 128: 513-520.
52. Derkatch IL, Uptain SM, Outeiro TF, Krishnan R, Lindquist SL, et al. (2004) Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro. Proc Natl Acad Sci U S A 101: 12934-12939.
53. Allen KD, Chernova TA, Tennant EP, Wilkinson KD, Chernoff YO, (2007) Effects of ubiquitin system alterations on the formation and loss of a yeast prion. J Biol Chem 282: 3004-3013.
54. Pagano M, (1997) Cell cycle regulation by the ubiquitin pathway. FASEB J 11: 1067-1075.
55. Al-Hakim A, Escribano-Diaz C, Landry MC, O'Donnell L, Panier S, et al. (2010) The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair 9: 1229-1240.
56. Singh RK, Kabbaj MH, Paik J, Gunjan A, (2009) Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis. Nat Cell Biol 11: 925-933.
57. Sleep D, Finnis C, Turner A, Evans L, (2001) Yeast 2 microm plasmid copy number is elevated by a mutation in the nuclear gene UBC4. Yeast 18: 403-421.
58. King MA, Hands S, Hafiz F, Mizushima N, Tolkovsky AM, et al. (2008) Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis. Mol Pharmacol 73: 1052-1063.
59. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 101: 3498-3503.
60. Krammer C, Kryndushkin D, Suhre MH, Kremmer E, Hofmann A, et al. (2009) The yeast Sup35NM domain propagates as a prion in mammalian cells. Proc Natl Acad Sci USA 106: 462-467.
61. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, et al. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67-78.
62. Chernoff YO, Galkin AP, Lewitin E, Chernova TA, Newnam GP, et al. (2000) Evolutionary conservation of prion-forming abilities of the yeast Sup35 protein. Mol Microbiol 35: 865-876.
63. Longtine MS, McKenzie A 3rd, Demarini DJ, Shah NG, Wach A, et al. (1998) Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14: 953-961.
64. Sherman F, (2002) Getting started with yeast. Methods Enzymol 350: 3-41.
65. Halfmann R, Lindquist S, (2008) Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp doi 10.3791/838.
66. Miller JH, (1972) Experiments in Molecular Genetics Cold Spring Harbor, NY Cold Spring Harbor Laboratory.
67. Lemoine FJ, Degtyareva NP, Lobachev K, Petes TD, (2005) Chromosomal translocations in yeast induced by low levels of DNA polymerase a model for chromosome fragile sites. Cell 120: 587-598.
68. Le Goff C, Zemlyanko O, Moskalenko S, Berkova N, Inge-Vechtomov S, et al. (2002) Mouse GSPT2, but not GSPT1, can substitute for yeast eRF3 in vivo. Genes Cells 7: 1043-1057.
69. Ter-Avanesyan MD, Kushnirov VV, Dagkesamanskaya AR, Didichenko SA, Chernoff YO, et al. (1993) Deletion analysis of the SUP35 gene of the yeast Saccharomyces cerevisiae reveals two non-overlapping functional regions in the encoded protein. Mol Microbiol 7: 683-692.
70. Serio TR, Cashikar AG, Moslehi JJ, Kowal AS, Lindquist SL, (1999) Yeast prion [psi+] and its determinant, Sup35p. Methods Enzymol 309: 649-673.
71. Laney JD, Hochstrasser M, (2003) Ubiquitin-dependent degradation of the yeast Matα2 repressor enables a switch in developmental state. Genes Dev 17: 2259-2270.
72. Firoozan M, Grant CM, Duarte JA, Tuite MF, (1991) Quantitation of readthrough of termination codons in yeast using a novel gene fusion assay. Yeast 7: 173-183.
73. Storici F, Resnick MA, (2006) The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast. Methods Enzymol 409: 329-345.
74. Sikorski RS, Hieter P, (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122: 19-27.
75. Newnam GP, Birchmore JL, Chernoff YO, (2011) Destabilization and recovery of a yeast prion after mild heat shock. J Mol Biol 408: 432-448.
76. Allen KD, Wegrzyn RD, Chernova TA, Mèuller S, Newnam GP, et al. (2005) Hsp70 chaperones as modulators of prion life cycle: novel effects of Ssa and Ssb on the Saccharomyces cerevisiae prion [PSI+]. Genetics 169: 1227-1242.
77. Narayanan V, Mieczkowski PA, Kim HM, Petes TD, Lobachev KS, (2006) The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. Cell 125: 1283-1296.
78. Argueso JL, Westmoreland J, Mieczkowski PA, Gawel M, Petes TD, et al. (2008) Double-strand breaks associated with repetitive DNA can reshape the genome. Proc Natl Acad Sci USA 105: 11845-11850.
79. DeRisi JL, Iyer VR, Brown PO, (1997) Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278: 680-686.
80. Wang P, Kim Y, Pollack J, Narasimhan B, Tibshirani R, (2005) A method for calling gains and losses in array CGH data. Biostatistics 6: 45-58.